You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

AC-PACL(DD); AC-PACL(DD)+TRAS

Cancer Type: Breast     Intent: Neoadjuvant, Adjuvant
Regimen Category: Evidence-Informed
Funding
New Drug Funding Program
  • Paclitaxel - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
  • Paclitaxel - Neoadjuvant Treatment for Non-Metastatic Breast Cancer
New Drug Funding Program
  • Trastuzumab - Adjuvant Treatment for HER2_neu-Overexpressing Primary Breast Cancer
Evidence Building Program
  • Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
  • Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental
Regimen Information Sheet
What is this treatment for?
  • View Patient Info Sheet
    AC-PACL (DD) is the code name of your breast cancer treatment regimen.
    A regimen is a combination of medications to treat cancer.

For more links on how to manage your symptoms go to www.cancercareontario.ca/symptoms.

The information set out in the medication information sheets, regimen information sheets, and symptom management information(for patients) contained in the Drug Formulary (the "Formulary") is intended to be used by health professionals and patients for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or side effects of a certain drug, nor should it be used to indicate that use of a particular drug is safe, appropriate or effective for a given condition.

A patient should always consult a healthcare provider if he/she has any questions regarding the information set out in the Formulary. The information in the Formulary is not intended to act as or replace medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.